IP Library › Granted Patent US 12,109,442
Granted Patent B2
US 12,109,442 · App. 15/539,230 · Granted Oct 8, 2024

Oral care compositions and methods of use

Inventors: Wilbens Josias (North Plainfield, NJ); Richard Robinson (Belle Mead, NJ); Adam Pepperney (Easton, PA); Kimdra Smith-Webster (Williamstown, NJ)
Assignee: Colgate-Palmolive Company
A61Q11/00A61K8/19A61K8/24A61K8/27A61K8/34A61K8/44A61K8/466A61K8/49
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,109,442
App. No.
15/539,230
Granted
Oct 8, 2024
Kind
B2
Abstract

This invention relates to oral care compositions comprising a basic amino acid or salt thereof, a zinc source, and a preservative, as well as to methods of using and of making these compositions.

Claims (10)

1. An oral care composition comprising:

arginine, in free or salt form;

a mixture comprising zinc oxide and zinc citrate;

a preservative, wherein the preservative is benzyl alcohol, wherein the benzyl alcohol is in an amount of 0.7% by wt., wherein the arginine is present in an amount of 1% to 15% wt. based on the weight of the oral care composition, the weight of the arginine being calculated as free base form, wherein zinc oxide is present in an amount of 1% wt. based on the weight of the oral care composition, and wherein the zinc citrate is in an amount of from 0.5% wt. based on the weight of the oral care composition; and

wherein the pH of the oral care composition is between 7.5 and 10.5.

2. The oral care composition of claim 1 , wherein the arginine is L-arginine.

3. The oral care composition of claim 1 , wherein the arginine is present at about 8% wt.

4. The oral care composition of claim 1 , wherein the ratio of zinc oxide to zinc citrate is 2:1.

5. The oral care composition of claim 1 , wherein the composition further comprises tetrasodium pyrophosphate, and wherein the tetrasodium pyrophosphate is in an amount of 0.2%-1.0% wt. based on the weight of the oral care composition.

6. The oral care composition of claim 1 , wherein the composition further comprises tetrasodium pyrophosphate, and wherein the tetrasodium pyrophosphate is in an amount of about 0.5% wt. based on the weight of the oral care composition.

Continuity (1)
Related Publication 20170348550A1 · Dec 7, 2017